Xiamen Traditional Chinese Medicine Co., Ltd. Report issue

Government Phase 4

Organization Overview

First Clinical Trial
2018
NCT03515369
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Xiamen Traditional Chinese Medicine Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

babaodan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Recurrence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1